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ABSTRACT: Aims. To evaluate the long-term clinical outcomes fol-
lowing percutaneous coronary intervention (PCI) with the Genous stent 
in an unselected population. Methods. All patients admitted to a single 
center who underwent PCI using the GS exclusively, between May 2006 
and May 2012, were enrolled, and a clinical follow-up of up to 60 months 
was carried out. The primary endpoint of major adverse cardiac event 
(MACE) rate was defined as the composite of cardiac death, acute myocar-
dial infarction (AMI), and target lesion revascularization (TLR). Results. 
Of the 450 patients included (75.1% male; 65.5 ± 11.7 years), 28.4% were 
diabetic and acute coronary syndrome was the reason for PCI in 76.4%. 
Angioplasty was performed in 524 lesions using 597 Genous stents, with 
angiographic success in 97.1%. At a median of 36 months of follow-up 
(range, 1-75 months), MACE, AMI, TLR, stent restenosis (SR), and stent 
thrombosis (ST) rates were 15.6%, 8.4%, 4.4%, 3.8%, and 2.2%, respec-
tively. Between 12 and 24 months, the TLR, SR, and ST rates practically 
stabilized, up to 60 months. Bifurcation lesions were independently associ-
ated with MACE, TLR, and SR. Conclusion. This is the first study report-
ing clinical results with the Genous stent up to 60 months. The Genous 
stent was safe and effective in the long-term, in an unselected population.  
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The Genous bioengineered R stent (GS; OrbusNeich) is 
covered by monoclonal CD34+ antibodies that selectively cap-
ture circulating endothelial progenitor cells, thus accelerating 
healing of the stented lesion.1,2
Many studies have been published on the safety and effec-
tiveness of the GS, but the studies with the longest follow-up 
reported the clinical outcomes at 36 months following percuta-
neous coronary intervention (PCI) with the GS3,4 and one study 
included only ST-elevation myocardial infarction patients.4 We 
aimed to evaluate the clinical outcomes up to 60 months fol-
lowing PCI with the GS in an unselected population.
Methods
Patients and data collection. We conducted a cohort study 
of all patients admitted to our center treated with PCI exclu-
sively using the GS, between May 2006 and May 2012. The 
study protocol was approved by the hospital ethics committee 
and all patients signed informed consent forms before PCI.
Based on the clinical files, the following data were recorded: 
demographic and clinical data, including cardiovascular risk 
factors, previous cardiovascular events, and other comorbidi-
ties; angiographic and PCI procedural data; and in-hospital 
clinical and angiographic complications.
Based on phone enquiry or clinic visits, a clinical follow-up 
at 1, 12, 36, and 60 months after discharge was carried out. 
The study was concluded 1 month after the last patient was 
enrolled and at the end of the study all patients or their rep-
resentatives (in case of death) were contacted. The following 
data were accounted for and verified by hospital records: death, 
acute myocardial infarction (AMI), target vessel revasculariza-
tion (TVR), target lesion revascularization (TLR), clinical stent 
restenosis, stent thrombosis, angina or anginal equivalent, and 
dual-antiplatelet therapy discontinuation.
Patients who received a stent other than the GS, either in 
the same PCI where the GS was implanted or in a staged PCI, 
were excluded. 
Endpoint. The primary endpoint of major adverse car-
diac event (MACE) rate was defined as the composite of car-
diac death, AMI, and TLR. Clinical stent restenosis and stent 
thrombosis incidence were also determined.
Definitions. All deaths were considered cardiac deaths un-
less otherwise documented. AMI was defined in accordance 
with the Academic Research Consortium (ARC)5 as elevation 
of cardiac enzymes 3 times the upper limit of normal. TVR was 
defined as repeat revascularization of the previously treated ves-
sel, and TLR as repeat revascularization within 5 mm to stent 
edges (in-segment). Clinical stent restenosis was defined as the 
presence of angina or anginal equivalent, associated with >50% 
stenosis in the segment covered by the stent or the adjacent 5 
mm. Stent thrombosis was classified according to ARC defi-
nitions,5 in which definite stent thrombosis is defined as angio-
graphic or pathologic confirmation of acute stent thrombosis 
in patients with acute coronary syndromes; and probable stent 
thrombosis as any unexplained death in the 30 days following 
stent implantation or as target vessel myocardial infarction 
without angiographic confirmation of stent thrombosis or 
other identified culprit lesion. Stent thrombosis was classified 
as acute (first 24 hours), subacute (between 24 hours and 30 
days), and late (after 30 days). Angiographic success was de-
fined as residual stenosis of less than 10% and Thrombolysis in 
Myocardial Infarction (TIMI) flow score 3.
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Table 1. Demographic and clinical data.
Characteristic n = 450
Male 338 (75.1%)
Hypertension 335 (74.4%)
Dyslipidemia 304 (67.6%)
Smoking history 159 (35.3%)
Diabetes mellitus 128 (28.4%)
Obesity 103 (22.9%)
Previous AMI 28 (6.2%)
Previous percutaneous coronary intervention 57 (12.7%)
Previous coronary artery bypass grafting 9 (2.0%)
Predischarge depressed LVEF (<55%) 181 (40.2%)
Cardiogenic shock 8 (1.8%)
Reason for performing PCI
   AMI without ST elevation 161 (35.8%)
   AMI with ST elevation 151 (33.6%)
   Stable coronary artery disease 106 (23.6%)
   Unstable angina 32 (7.1%)
Data given as n (%). LVEF = left ventricular ejection fraction; AMI = 
acute myocardial infarction; PCI = percutaneous coronary intervention.
Table 2. Angiographic data.
Characteristic n = 450
Multivessel disease 202 (44.9%)
Lesions treated per patient
   1 364 (80.9%)
   >1 86 (19.1%)
Intervened vessel n = 524
   Left anterior descending artery 226 (43.1%)
   Right coronary artery 178 (34.0%)
   Circumflex artery 114 (21.8%)
   Left main artery 4 (0.8%)
   Venous bypass graft 2 (0.4%)
Lesion risk profile n = 524
   Lesion type B2/C 254 (48.5%)
   Long lesion 133 (25.4%)
   Bifurcation lesion 53 (10.1%)
   Calcified lesion 64 (12.2%)
   Eccentric lesion 315 (60.1%)
   Thrombotic lesion 111 (21.2%)
   Restenosis (previous angioplasty with
      another stent)
7 (1.3%)
Table 3. Procedural data. 
Pre Intervention Post Intervention
TIMI flow score N n (%) n (%)
   0
524 lesions
135 (25.8%) 1 (0.2%)
   1 37 (7.1%) 1 (0.2%)
   2 22 (4.2%) 6 (1.1%)
   3 330 (63.0%) 516 (98.5%)
N n (%)
Number of stents per patient
450 patients   1 314 (69.8%)
   >1 136 (30.2%)
Stent implantation
   Diameter of the stent (mm)
597 stents
3.00 (2.50-4.00)
   Length of the stent (mm) 15 (9-33)
   Pressure of inflation (atm) 18 (10-24)
   Duration of inflation (s) 20 (10-50)
Post dilatation
   Diameter of the balloon (mm)
524 lesions with
50 post dilatations
(9.5%)
3.00 (2.50-4.00)
   Length of the balloon (mm) 12 (6-28)
   Pressure of insufflation (atm) 16 (10-20)
   Duration of inflation (s) 20 (10-60)
Kissing balloon 53 bifurcation lesions 10 (18.9%)
Glycoprotein IIb/IIIa inhibitor (abciximab or tirofiban) 450 patients 132 (29.3%)
Thrombus aspiration 450 patients 28 (6.2%)
Discrete data given as n (%) and continuous variables as median (minimum-maximum). TIMI = Thrombolysis in Myocardial Infarction. 
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Statistical analysis. Discrete data are presented as frequency 
(percentage), whereas continuous variables are presented as mean ± 
standard deviation or as median (range), when appropriate. Cumu-
lative survival rates were estimated using the Kaplan-Meier method. 
A Cox proportional hazard multivariate analysis was used to identify 
independent predictors of MACE, TLR, and clinical stent restenosis 
by backward selection of all demographic, clinical, angiographic and 
procedural data. The estimated survival free from MACE, TLR, and 
clinical stent restenosis were compared between patients with and 
without bifurcation lesions using a log-rank test (post hoc analysis). A 
P-value of less than .05 was considered statistically significant. Data 
were analyzed using the software Statistical Package for the Social 
Science for Windows, version 16.0 (SPSS, Inc).
Results
PCI using the GS was performed in 468 patients and 18 were 
excluded since they received another type of stent in addition to the 
GS. In our cohort of 450 patients, a total of 338 (75.1%) were male 
and the mean age was 65.5 ±11.7 years. Demographic and clinical 
data are presented in Table 1. A total of 128 patients (28.4%) had 
diabetes mellitus on medication. Acute coronary syndrome was the 
most frequent reason for performing PCI (76.4%).
Angiographic data are presented in Table 2. Angioplasty was per-
formed in 524 lesions, of which 226 (43.1%) were located in the left 
anterior descending artery and 254 (48.5%) were classified as type 
B2/C.6 Fifty-three lesions (10.1%) were bifurcations (bifurcation 
type I in 31 patients, type II in 11 patients, and type III in 11 pa-
tients).7 Mean stenosis of the intervened lesions was 91.1 ± 10.9%.
Procedural data is presented in Table 3. Angiographic suc-
cess was achieved in 509 angioplasties (97.1%), and complete 
revascularization in 314 patients (69.8%). A total of 597 Ge-
nous stents were used (1.1/lesion). The median diameter of the 
stent implanted was 3.00 mm (2.50-
4.00 mm) and the median length was 
15 mm (9-33 mm). 
Follow-up. Follow-up data were ob-
tained from all patients. Median follow-
up period was 36 months (1-75 months), 
since the last included patients had not 
completed 60 months after discharge at 
the end of the study. The clinical events 
that occurred during this period are pre-
sented in Table 4 and cumulative survival 
free from clinical events up to 60 months 
is presented in Figure 1. MACE, cardiac 
death, and AMI rates continued to in-
crease up to 60 months. Conversely, TLR, 
clinical stent restenosis, and stent throm-
bosis rates stabilized between 12 and 24 
months post PCI and maintained rela-
tively stable up to 60 months (Figure 1). 
Eight definite stent thromboses oc-
curred (Table 4): 1 acute, 4 subacute 
(on days 2, 10, 11, and 21) and 3 late 
(months 2, 4, and 48). One subacute 
stent thrombosis was probably due to 
relative antiplatelet underdosing (100 
mg acetylsalicylic acid plus 75 mg clopidogrel/day, despite a body 
weight of 141 kg). In another subacute stent thrombosis, the pa-
tient had previously discontinued antiplatelet therapy, against 
medical advice. No apparent stent abnormalities were found in the 
subsequent angiographies. PCI was performed with success in 7 
patients; 1 patient underwent coronary artery bypass grafting since 
the left main artery was involved; all 8 patients survived. There 
were 2 probable stent thromboses: a sudden unexplained death 9 
days after PCI (in ambulatory), and a death caused by AMI in 
a patient that was not catheterized and whose autopsy revealed a 
target-vessel AMI.
At 1 month and 12 months of follow-up, 95.3% and 57.6% 
of the patients were on dual-antiplatelet therapy, respectively.
Multivariate predictors of MACE, TLR, and clinical stent re-
stenosis are presented in Table 5. Bifurcation lesion was the most 
important predictor of MACE and clinical stent restenosis and was 
the only predictor of TLR. At 60 months, estimated survival free 
from events was significantly lower for patients with bifurcation 
lesions in comparison with patients without bifurcation lesions, 
regarding MACE (log-rank test, P<.001), TLR (log-rank test, 
P=.01), and clinical stent restenosis (log-rank test, P=.01).
Discussion
This single-center study evaluated the long-term safety and ef-
fectiveness of the GS in an unselected population. The GS evi-
denced a good performance following PCI, probably related to the 
rapid endothelialization.8 The rates of MACE, cardiac death, TVR, 
TLR, clinical stent restenosis, and stent thrombosis were low. 
Few studies reported the clinical outcomes beyond 36 months 
after PCI with stent placement in all-comer populations,9 and 
the longest follow-up study after PCI with the GS had a dura-
tion of 36 months.3 In this study on 405 unselected patients, the 
Figure 1. Estimated survival free from clinical events (above) and continuous rate of dual-anti-
platelet therapy (below). AMI = acute myocardial infarction; DAPT = dual-antiplatelet therapy; 
death = cardiac death; MACE = major adverse cardiac events; SR = clinical stent restenosis; ST = 
stent thrombosis; TLR = target lesion revascularization; # at risk (MACE) = number of patients at 
risk of major adverse cardiac events.
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primary endpoint of target lesion failure, defined as the compos-
ite of cardiac death, AMI, and TLR, was 18.3% and the need 
for TLR was 14.2%; definite and probable stent thrombosis oc-
curred in 0.5% and 1.0%, respectively, and no cases of definite 
late or very late stent thrombosis were reported. In another study 
on 100 ST-elevation AMI patients who also received a GS, the 
rate of MACE, defined as cardiac death, AMI, and TLR, was 
15.8% at a mean follow-up of 34 months and there were no cases 
of definite stent thrombosis.4 Our data compare well with these 
studies on the long-term outcomes after PCI with the GS.
In our cohort, although MACE, cardiac death, and AMI contin-
ued to increase up to 60 months, the need for TLR, clinical stent re-
stenosis, and stent thrombosis rates practically stabilized from 12 to 
24 months, up to 60 months. This suggests that “GS failure” did not 
account for the sustained increase in MACE, death, or AMI. The 
deflecting TLR curve after the first year of PCI with the GS has been 
reported by Klomp et al.3 Duckers et al8 demonstrated late intimal 
tissue regression, with a luminal loss reduction of 24.4% between 
the 6- and 18-month of angiographic follow-up. In contrast, the risk 
of TLR after the first year of stent implantation may be higher and 
ongoing in patients treated with a drug-eluting stent.10
In our patients, bifurcation lesion was independently associat-
ed with MACE, TLR, and stent restenosis. In the study by Beijk 
el at,11 where 573 patients were treated for at least 1 bifurcation 
lesion with the GS, the TLR rate was 12.7% at 12 months. These 
data suggest that bifurcation lesions may predict worse outcomes 
with the GS in comparison with non-bifurcation lesions.
Study limitations. This study has the limitation of reflect-
ing the experience of a single center. In addition, the stent type 
was selected at the discretion of the operators and patients with 
higher thrombotic risk or lower dual antiplatelet therapy compli-
ance might have been preferentially selected to receive the GS. 
Nevertheless, this possible bias would worsen the endpoint rates, 
which have been low in this cohort.
Conclusion
The GS had a long-term favorable profile in a “real-world” 
unselected population. The TLR, stent restenosis, and stent 
thrombosis rates stabilized between 12 and 24 months, up to 
60 months following PCI. Except in bifurcation lesions, the GS 
was safe and effective and may be a good option, considering the 
long-term clinical results.
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Table 4. Clinical events during follow-up: median follow up, 
36 months (range 1-75 months).
Patients N = 450
Major adverse cardiac events 70 (15.6%)
Death 57 (12.7%)
   Cardiac 29 (6.4%)
   Non-cardiac 28 (6.2%)
Acute myocardial infarction 38 (8.4%)
Target vessel revascularization 25 (5.6%)
Target lesion revascularization 20 (4.4%)
   Coronary artery bypass grafting 4 (0.9%)
   Percutaneous coronary intervention 16 (3.6%)
Clinical stent restenosis 17 (3.8%)
Stent thrombosis 10 (2.2%)
   Definite 8 (1.8%)
      Acute 1 (0.2%)
      Subacute 4 (0.9%)
      Late 3 (0.7%)
   Probable 2 (0.4%)
Table 5. Multivariate predictors of major adverse cardiac 
events, target lesion revascularization and clinical stent 
restenosis.
Major adverse cardiac 
events
HR 95% CI P-Value
Bifurcation lesion 2.868 1.575-5.220 .01
Diabetes mellitus 2.054 1.238-3.408 .01
Depressed LVEF (<55%) 1.973 1.192-3.263 .01
Higher TIMI score (post 
intervention)
0.325 0.129-0.815 .02
Target lesion revascularization
Bifurcation lesion 4.406 1.559-10.811 .01
Clinical stent restenosis
Bifurcation lesion 4.705 1.602-13.814 .01
Higher residual stenosis 
(post intervention)
1.070 1.024-1.118 .01
TIMI = Thrombolysis in Myocardial Infarction; LVEF = left ventricular 
ejection fraction.
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